Nuvalent’s ALK inhibitor gets Priority Review as lung cancer treatment sequencing evolves
Nuvalent’s neladalkib has FDA Priority Review in ALK-positive lung cancer. Find out why resistance and brain metastases drive the story.
Pharma & Biotech